DE69233124D1 - Verwendung von reinem fluoxetin-s(+)-isomer für die herstellung eines medikements gegen migräne - Google Patents

Verwendung von reinem fluoxetin-s(+)-isomer für die herstellung eines medikements gegen migräne

Info

Publication number
DE69233124D1
DE69233124D1 DE69233124T DE69233124T DE69233124D1 DE 69233124 D1 DE69233124 D1 DE 69233124D1 DE 69233124 T DE69233124 T DE 69233124T DE 69233124 T DE69233124 T DE 69233124T DE 69233124 D1 DE69233124 D1 DE 69233124D1
Authority
DE
Germany
Prior art keywords
pure
isomer
fluoxetine
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69233124T
Other languages
English (en)
Other versions
DE69233124T2 (de
Inventor
James W Young
Timothy J Barberich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of DE69233124D1 publication Critical patent/DE69233124D1/de
Publication of DE69233124T2 publication Critical patent/DE69233124T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69233124T 1991-11-15 1992-02-05 Verwendung von reinem fluoxetin-s(+)-isomer für die herstellung eines medikements gegen migräne Expired - Fee Related DE69233124T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79303691A 1991-11-15 1991-11-15
US793036 1991-11-15
PCT/US1992/000888 WO1993009769A1 (en) 1991-11-15 1992-02-05 Methods and compositions utilizing pure s(+) isomer fluoxetine

Publications (2)

Publication Number Publication Date
DE69233124D1 true DE69233124D1 (de) 2003-08-14
DE69233124T2 DE69233124T2 (de) 2004-02-19

Family

ID=25158891

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69233124T Expired - Fee Related DE69233124T2 (de) 1991-11-15 1992-02-05 Verwendung von reinem fluoxetin-s(+)-isomer für die herstellung eines medikements gegen migräne

Country Status (9)

Country Link
EP (2) EP1208838A3 (de)
JP (2) JPH07500812A (de)
AT (1) ATE244563T1 (de)
AU (2) AU1373692A (de)
CA (1) CA2123704C (de)
DE (1) DE69233124T2 (de)
DK (1) DK0612242T3 (de)
ES (1) ES2197144T3 (de)
WO (1) WO1993009769A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174864T3 (es) * 1993-06-28 2002-11-16 Wyeth Corp Nuevos tratamientos que utilizan derivados de fenetilo.
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
ES2103682B1 (es) * 1995-09-20 1998-04-01 Lilly Sa Composicion farmaceutica oral de fluoxetina, solida y con caracteristicas organolepticas mejoradas.
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6846957B2 (en) 2002-11-22 2005-01-25 Board Of Regents, The University Of Texas System Synthesis of 3-aminomethyl-1-propanol, a fluoxetine precursor
CN111643475A (zh) * 2020-07-20 2020-09-11 华益药业科技(安徽)有限公司 一种氟西汀胶囊生产工艺

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA817863B (en) * 1980-11-14 1983-06-29 Lilly Co Eli (-)n-methyl-3-(2-methylphenoxy)-3-phenylpropylamnie,antidepressant

Also Published As

Publication number Publication date
DE69233124T2 (de) 2004-02-19
EP0612242B1 (de) 2003-07-09
EP0612242A4 (en) 1997-01-15
EP1208838A2 (de) 2002-05-29
DK0612242T3 (da) 2003-10-20
ATE244563T1 (de) 2003-07-15
AU1891797A (en) 1997-06-19
CA2123704A1 (en) 1993-05-27
JPH07500812A (ja) 1995-01-26
CA2123704C (en) 2003-01-21
EP1208838A3 (de) 2003-07-09
AU1373692A (en) 1993-06-15
ES2197144T3 (es) 2004-01-01
EP0612242A1 (de) 1994-08-31
WO1993009769A1 (en) 1993-05-27
JP2004002474A (ja) 2004-01-08

Similar Documents

Publication Publication Date Title
DE69012261D1 (de) Verwendung von Sertralin zur Behandlung verfrühter Ejakulation.
ATE212223T1 (de) Verwendung von sertraline zur herstellung eines arzneimittels zur behandlung von obsessiv- kompulsiven erkrankungen
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
DE236684T1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
DE59109222D1 (de) Verwendung des Wirkstoffs Flupirtin zur Herstellung eines Arzneimittels zur Bekämpfung von Muskelverspannungen
DE69428268D1 (de) Verwendung von lokalanaesthetika zur herstellung eines arzneimittels zur behandlung von bronchialasthma
DE69233124D1 (de) Verwendung von reinem fluoxetin-s(+)-isomer für die herstellung eines medikements gegen migräne
HUP0401934A2 (hu) Enantiomerekben dúsított demetil- és didemetil- citalopram metabolitok alkalmazása depresszió és más központi idegrendszeri rendellenességek esetében
DE69620027T2 (de) Verwendung von eliprodil zur herstellung eines arzneimittels zur behandlung von ischämischen störungen der retina oder des sehnervs
ATE235237T1 (de) Sertralin zur behandlung von post-myocard-infarkt-patienten
BG98684A (en) 3-(n-isopropyl-n-h-propylamino)-5-(n-isopropyl) carbonoylchroman
PH27544A (en) A method of treating chemical dispendencies using sertraline
DE69424415D1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
DE69620394T2 (de) Verwendung von forskolin oder diese enthaltende extrakte zur herstellung eines medikaments für die behandlung von alkoholsucht
HK113897A (en) The use of BMY 14802 in the treatment of anxiety in benzodiazepine-withdrawn patients
ATE232098T1 (de) Verwendung von efaroxan zur herstellung eines arzneimittels zur behandlung von huntington krankheit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee